CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum
Head-to-head drug comparisons, new combination therapies, and oral medications are expanding treatment options for people with heart-kidney-metabolic disease.
The 11th CVOT Summit report (60+ global experts) highlights 2025 landmark advances in the CKM space: the first head-to-head CVOT (SURPASS-CVOT), combination CKM therapy (finerenone+empagliflozin CONFIDENCE trial), the oral GLP-1 RA orforglipron showing efficacy in ATTAIN-1, and the novel aldosterone synthase inhibitor baxdrostat. Continuous glucose and ketone monitoring advances and expanded metabolic disease indications are also highlighted.
What the study was
- Study design
- Multi-expert conference summary (11th CVOT Summit, 60+ authors)
- Population
- CKM continuum patients across cardiology, nephrology, endocrinology, hepatology
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cardiovascular Diabetology
Why it surfaced
Authoritative annual CVOT summit report with 60+ cardiometabolic experts synthesizing 2025 pivotal trial results; highlights multiple novel agents and first head-to-head CVOT directly on watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.